Abstract
Fluoroquinolones (FQs) are the most common and widely prescribed antibiotics while having broad spectrum used for the treatment of various diseases caused by bacteria's. Various clinical reports reveals that fluoroquinolones causes significant dysglycemic affects. This work was designed to investigate the mechanism of hypoglycemic effect of Moxifloxacin on molecular docking level. From the results it is revealed Moxifloxacin showing hypoglycemic effects supporting the literature by interacting with glycogen synthase kinase-3 enzymes by serine and threonine active sites of target with ligand. It is the need of the day to properly understand the exact mechanism of hypoglycemia induced by Moxifloxacin by performing further preclinical and clinical trials so that to identify various methodologies to get rid of harmful effects of Moxifloxacin in disease conditions specially in diabetes mellitus.